Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Company facts
Early-stage
- Founded
- 2021
- Employees
- 15
- Headquarters
- United States
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.